Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:34 2024-05-29 am EDT			5-day change	1st Jan Change
71.1 ^SEK	-5.70%		+21.33%	+77.75%

May. 23	Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	CI
May. 20	Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	CI

Xspray Pharma Q1 2024 - Reveal of XS025 and PDUFA is nearing

May 13, 2024 at 02:25 am EDT

Redeye updates its view on Xspray Pharma following an undramatic Q1 2024 report. The company has recently raised SEK100m through TO6, unveiled XS025 targeting cabozantinib, and the Dasynoc PDUFA date is less than three months away. We raise our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Xspray Pharma AB

Xspray Pharma AB Announces to Present Data At ASCO Highlighting Frequent Decideication of PPIs with TKIs in CML-Patients and Greater Than Expected Positive Effects on the Bioavailability of Crystalline Dasatinib	May. 23	CI
Xspray Pharma AB Appoints Linda Glimberg as Chief Operating Officer, Effective June 1, 2024	May. 20	CI
Xspray Pharma AB Appoints Niklas Adenborg as Chief Financial Officer, Effective July 1, 2024	May. 20	CI
Xspray Pharma Announces Fourth Product Candidate, Targeting USD 2.3 Billion Market	Apr. 22	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 14	CI
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	Feb. 12	MT
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	Feb. 12	CI
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	Feb. 07	CI
Xspray Pharma AB Announces CFO Changes	Feb. 07	CI
Xspray Pharma Ab's Xs003 Achieves Superior Bioavailability Milestone, Matching TASIGNA At Reduced Dosage	Nov. 21	CI
Xspray Pharma AB Through HyNap? technology Announces Results from Drug Interaction Studies	Nov. 08	CI
Xspray Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Xspray Pharma AB Announces Nomination Committee for the Annual General Meeting 2024	23-10-24	CI
Certain Shares of Xspray Pharma AB are subject to a Lock-Up Agreement Ending on 25-SEP-2023.	23-09-24	CI
Xspray Pharma Names Chief Commercial Officer	23-09-15	MT
Xspray Pharma Appoints Edward P. Jordan as Chief Commercial Officer	23-09-15	CI
Xspray Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
US FDA Requests More Data from Xspray Pharma for Dasynoc Drug Candidate; Shares Fall 7%	23-07-11	MT
Xspray Pharma AB Receives Request for Additional Information Concerning Dasynoc from FDA	23-07-11	CI
Xspray Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Xspray Pharma AB Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Xspray Pharma AB Partners with EVERSANA® for the U.S. Launch and Commercialization of its Lead Product, Dasynoc for the Treatment of Chronic Myeloid Leukemia and Acute Lymphatic Leukemia	23-02-23	CI
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Xspray Pharma AB(OM:XSPRAY) added to OMX Nordic Small Cap Index	23-01-03	CI

Chart Xspray Pharma AB

Duration

Period

More charts

Company Profile

XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-06-03 - American Society of Clinical Oncology Meeting - Abstract No :6561

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

75.4 SEK

Average target price

107 SEK

Spread / Average Target

+41.91%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
XSPRAY PHARMA AB	+77.75%	197M
VERTEX PHARMACEUTICALS INCORPORATED	+8.38%	115B
REGENERON PHARMACEUTICALS, INC.	+10.13%	105B
BIONTECH SE	-11.69%	22.71B
ARGENX SE	+2.21%	21.83B
GENMAB A/S	-10.88%	18.18B
WUXI APPTEC CO., LTD.	-41.90%	16.52B
BEIGENE, LTD.	-16.00%	16.01B
NEUROCRINE BIOSCIENCES, INC.	+2.28%	14.14B
SAREPTA THERAPEUTICS, INC.	+20.54%	10.71B

Bio Therapeutic Drugs